Establishment of PDX-derived oral cancer cell lines and utility of anti-HER2 antibody therapy

被引：0
|
作者：
Seki, Yuki [1 ]
Kariya, Ryusyo [2 ]
Yoshida, Ryoji [3 ]
Kawahara, Kenta [3 ]
Hirayama, Masatoshi [3 ]
Nakamoto, Masafumi [3 ]
Hirosue, Akiyuki [3 ]
Okada, Seiji [2 ]
Nakayama, Hideki [3 ]
机构：
[1] Kumamoto Univ, Grad Sch Med Sci, Kumamoto, Japan
[2] Kumamoto Univ, Div Hematopoiesis Joint Res Ctr Human Retrovirus, Kumamoto, Japan
[3] Kumamoto Univ, Fac Life Sci, Dept Oral & Maxillofac Surg, Kumamoto, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2238
引用
收藏
页码：990 / 990
页数：1
相关论文
共 50 条
  • [41] Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia
    Ito, A
    Kuga, Y
    Honda, H
    Kikkawa, H
    Horiuchi, A
    Watanabe, Y
    Kobayashi, T
    CANCER LETTERS, 2004, 212 (02) : 167 - 175
  • [42] A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
    Ohta, M
    Tokuda, Y
    Suzuki, Y
    Kubota, M
    Watanabe, T
    Fujii, H
    Sasaki, Y
    Niwa, T
    Makuuchi, H
    Tajima, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (11) : 553 - 556
  • [43] Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
    Madrid-Paredes, Adela
    Canadas-Garre, Marisa
    Sanchez-Pozo, Antonio
    Angel Calleja-Hernandez, Miguel
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 493 - 505
  • [44] BREAST CANCER BIOMARKERS AND HER2 TESTING AFTER 10 YEARS OF ANTI-HER2 THERAPY
    Ross, Jeffrey S.
    DRUG NEWS & PERSPECTIVES, 2009, 22 (02) : 93 - 106
  • [45] Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer
    Adela Madrid-Paredes
    Marisa Cañadas-Garre
    Antonio Sánchez-Pozo
    Miguel Ángel Calleja-Hernández
    Breast Cancer Research and Treatment, 2015, 153 : 493 - 505
  • [46] Anti-HER2 therapy for HER2-positive metastatic breast cancer: regimens and treatment outcomes
    Watanabe, Kenichi
    Hagio, Kanako
    Baba, Motoi
    Ikarashi, Mayuko
    Sato, Masako
    Tomioka, Nobumoto
    Takahashi, Masato
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [47] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    LABORATORY INVESTIGATION, 2018, 98 : 91 - 91
  • [48] New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
    Ian A. MacNeil
    David J. Burns
    Benjamin E. Rich
    Sajjad M. Soltani
    Samantha Kharbush
    Nicole G. Osterhaus
    Brian F. Sullivan
    Douglas M. Hawkins
    Jodie R. Pietruska
    Lance G. Laing
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 605 - 619
  • [49] New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
    MacNeil, Ian A.
    Burns, David J.
    Rich, Benjamin E.
    Soltani, Sajjad M.
    Kharbush, Samantha
    Osterhaus, Nicole G.
    Sullivan, Brian F.
    Hawkins, Douglas M.
    Pietruska, Jodie R.
    Laing, Lance G.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 605 - 619
  • [50] Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
    Kim, H.
    Danishmalik, S. N.
    Hwang, H.
    Sin, J-I
    Oh, J.
    Cho, Y.
    Lee, H.
    Jeong, M.
    Kim, S-H
    Hong, H. J.
    CANCER GENE THERAPY, 2016, 23 (10) : 341 - 347
12345